Monday, 18 October 2021 03:58 GMT

CannabisNewsBreaks InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition


(MENAFN- Investor Brand Network) InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing and clinical development of rare cannabinoids, has finalized the acquisition of BayMedica Inc., a private company based in the U.S. specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. INM had announced the acquisition earlier. According to the announcement, the acquisition provides capabilities and resources to accelerate InMed's commercial initiatives, including the development and unveiling of several new cannabinoids products in the consumer health and wellness sector. The combined technologies include synthetic biology, chemical synthesis and IntegraSyn(TM), a patented enzymatic biotransformation. The company noted that, with the acquisition, it will become a market leader in the manufacturing of rare cannabinoids.“We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team,” said InMed president and CEO Eric A. Adams in the press release.“In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the company to become a global leader in the manufacturing of rare cannabinoids.”

To view the full press releases, visit 

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing and development of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit  .

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company's newsroom at 

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text“CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit 

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: 

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado

303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork .

MENAFN14102021000224011066ID1102972738


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.